Recent Updates — AVXL
Anavex Life Sciences completed clinical conduct of two pharmacology studies for its lead drug candidate, blarcamesine: a Drug-drug Interaction (DDI) study with 65 participants and an Absorption, Distribution, Metabolism and Excretion (ADME) study with eight healthy volunteers. Preliminary observations reported no serious adverse events in either trial. Additionally, the U.S. Food and Drug Administration cleared the company's Investigational New Drug application for blarcamesine in Fragile X syndrome, allowing study start-up activities to proceed. The company also announced an upcoming FDA meeting in November regarding adding pediatric participants to its Phase 3 Rett syndrome study. Anavex is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases.
Anavex Life Sciences Corp. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for blarcamesine to treat Fragile X syndrome. This regulatory milestone allows the company to proceed with a planned Phase 2a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of blarcamesine oral solution in approximately 60 adult males with the condition. The clearance gives Anavex open INDs across all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases.
Anavex Life Sciences Corp. held its Annual Meeting of Stockholders on September 24, 2026, resulting in a contested election where six company-nominated directors were elected and none of the six nominees nominated by PVG Asset Management Corporation were selected. The contest triggered a 'Board Change Change in Control' provision under the company's incentive plans and the employment agreement with Principal Financial Officer Sandra Boenisch, causing all outstanding unvested awards to immediately vest. Voting results showed significant opposition for some directors, such as Dr. Jiong Ma receiving 37 million votes for against 14 million. The meeting also ratified Grant Thornton LLP as the independent auditor. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
Anavex Life Sciences Corp. announced on September 2, 2026, that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following a delinquency notification received in May 2026 due to the late filing of its Form 10-Q for the period ended March 31, 2026. The company submitted a compliance plan on July 20, 2026, and filed the outstanding quarterly reports for the periods ended March 31 and June 30, 2026, on August 28, 2026. Nasdaq confirmed the restoration of compliance, allowing Anavex's common stock to continue trading on the Nasdaq Global Select Market under the ticker AVXL without further delisting risk related to this specific filing requirement. This resolution mitigates near-term operational uncertainty regarding exchange listing status for the clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.
Anavex Life Sciences Corp. reported financial results for the third fiscal quarter ended June 30, 2026, posting a net income of $7.8 million, or $0.08 per share, compared to a net loss of $13.2 million in the prior year period. The turnaround was driven by reversals of stock-based compensation expense totaling $17.4 million associated with employee terminations, primarily the former CEO. Cash and cash equivalents rose to $118.3 million from $102.6 million at fiscal year-end September 30, 2025, providing a runway into mid-to-late fiscal 2028. Clinically, the company submitted all Alzheimer’s disease trial data to its new IND and plans to discuss Phase 3 protocol design with the FDA. It also submitted an FDA meeting request for Rett syndrome pediatric inclusion and expects to file an IND for Fragile X syndrome in September. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases.